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We previously reported hedgehog (Hh) signal activation in the mucus-secreting pit cell of the stomach and in diffuse-type gastric
cancer (GC). Epithelial–mesenchymal transition (EMT) is known to be involved in tumour malignancy. However, little is known about
whether and how both signallings cooperatively act in diffuse-type GC. By microarray and reverse transcription–PCR, we investigated
the expression of those Hh and EMT signalling molecules in pit cells and in diffuse-type GCs. How both signallings act cooperatively in
those cells was also investigated by the treatment of an Hh-signal inhibitor and siRNAs of Hh and EMT transcriptional key regulator
genes on a mouse primary culture and on human GC cell lines. Pit cells and diffuse-type GCs co-expressed many Hh and EMT
signalling genes. Mesenchymal-related genes (WNT5A, CDH2, PDGFRB, EDNRA, ROBO1, ROR2, and MEF2C) were found to be
activated by an EMT regulator, SIP1/ZFHX1B/ZEB2, which was a target of a primary transcriptional regulator GLI1 in Hh signal.
Furthermore, we identified two cancer-specific Hh targets, ELK1 and MSX2, which have an essential role in GC cell growth. These
findings suggest that the gastric pit cell exhibits mesenchymal-like gene expression, and that diffuse-type GC maintains expression
through the Hh–EMT pathway. Our proposed extensive Hh–EMT signal pathway has the potential to an understanding of diffuse-
type GC and to the development of new drugs.
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Gastric cancer (GC) is one of the most frequent fatal malignancies
in the world (Maxwell Parkin, 2001), and will be unresectable for
more than two-thirds of its sufferers. Even patients with an
operable tumour have a high rate of both local and distant
recurrence with a 5-year survival rate of less than 30%;
furthermore, the response rate to chemotherapy in unresectable
and recurrent cases is at most 40% (Wohrer et al, 2004; Lordick
and Siewert, 2005). Gastric cancers are histologically classified into
two major types: intestinal-type (clustered and well-differentiated,
and glandular-like types) and diffuse-type (infiltrating, poorly-
differentiated, and scattered types) (Lauren, 1965; Tatematsu et al,
1990; Ming, 1998; Yuasa, 2003). Intestinal-type GC develops
through some sequential stages including Helicobacter pylori
(H. pylori)-associated gastritis, intestinal metaplasia (IM), and
dysplasia. This type predominates in high-risk geographic areas,
such as east Asia, showing a correlation with the prevalence in the
region of H. pylori infection among the elderly. Diffuse-type
GC, however, is more uniformly distributed geographically, is
apparently unrelated to H. pylori prevalence and typically develops
from H. pylori-free, morphologically normal gastric mucosa
without atrophic gastritis, or IM. A de novo diffuse-type GC is
believed to develop from stem cells or precursors for gastric
epithelial cells in the background of relatively normal gastric
mucosa (Hohenberger and Gretschel, 2003; Schier and Wright,
2005). Unlike the decreasing incidence of the intestinal-type GC,
the prevalence of the diffuse type is reportedly increasing
worldwide (Crew and Neugut, 2006). Therefore, molecular
characterisation of diffuse-type GC, especially on infiltrating and
scattered type of growth or identification of cancer stem cell is
important for the development of new drugs for this type of
cancer. The infiltrating and scattered type of growth in diffuse-type
GC has been reported to be mediated by loss of E-cadherin (CDH1)
function through somatic mutation, promoter methylation, and
cancer-associated downregulation (Kountouras et al, 2005).
Recently, CDH1 has been reported to be downregulated by an
epithelial–mesenchymal transition (EMT) regulator, TWIST,
which plays an essential role in breast cancer metastasis, especially
of the diffuse type (Yang et al, 2004). However, a more detailed
signal network needs to be revealed to understand diffuse-type GC
growth and progression.
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selectively occurs in diffuse-type GC and that the Hh signal block
inhibits growth of GC cells with Hh activation (Fukaya et al, 2006).
In mammals, Hh ligands are composed of three members: Sonic
Hh (SHH), Indian Hh (IHH), and Desert Hh (DHH). Activation of
Hh signalling is initiated through binding of any of the above three
ligands to a 12-transmembrane protein receptor, PTCH, which acts
as a negative regulator of a 7-transmembrane protein, SMO.
Binding between Hh and PTCH results in de-repression of SMO,
thereby activating a cascade that leads to the translocation of the
active form of the transcription factor GLI to the nucleus. Nuclear
GLI activates expression of a variety of target genes such as BMP4,
FOXA2, ISL1, and FOXM1 (Krishnan et al, 1997; Van den Brink
et al, 2001; Teh et al, 2002). Recently, Ihog (interference Hh) and
Boi, which de-repress SMO through interaction with Hh ligands,
have been identified in Drosophila (Yao et al, 2006). Their mouse/
human homologues Boc/BOC and Cdo/CDO have the same
functions (Tenzen et al, 2006; Yao et al, 2006; Zhang et al, 2006).
Here we report that an EMT regulator SIP1 is a target of the Hh
signal in gastric pit cells and in diffuse-type GC, and that SIP1
regulates mesenchymal-related genes (WNT5A, CDH2, PDGFRB,
EDNRA, ROBO1, ROR2, and MEF2C), which express preferentially
in both pit cell and diffuse-type GC. Furthermore, we identified
two cancer-specific Hh targets, ELK1 and MSX2, which have an
essential role in tumour cell growth.
MATERIALS AND METHODS
Tissue samples
Gastric cancer and non-cancerous tissues were provided by the
National Cancer Center Hospital after obtaining informed consent
from each patient and approval by the Center’s Ethics Committee.
All cancer specimens were reviewed and classified histopatho-
logically according to the Japanese Classification of Gastric Cancer.
Tissue specimens were immediately frozen with liquid nitrogen
after surgical extraction, and stored at  801C until use.
Microarray analysis
Total RNA was isolated by suspending the cells in an ISOGEN
lysis buffer (Nippon Gene, Toyama, Japan), followed by
precipitation with isopropanol. We used Human Expression Array
U95A version 2 (Affymetrix, Santa Clara, CA, USA) for analysis of
mRNA expression levels corresponding to 12600 transcripts. The
procedures were conducted according to the supplier’s protocols.
The expression value (average difference; AD) of each gene was
calculated using GeneChip Analysis Suite version 4.0 software
(Affymetrix). The mean of AD values in each experiment was 1000
to reliably compare variable multiple arrays.
Laser microdissection (LMD), RNA extraction, RT–PCR,
and quantitative real-time PCR
The cryostat sections (8mm) of frozen tissues were microdissected
with a Pixcell II LCM system (Arcturus Engineering, Mountain
View, CA, USA). Total RNA was isolated by suspending the cells in
an ISOGEN lysis buffer (Nippon Gene), followed by precipitation
with isopropanol. The mRNA was amplified by an efficient method
of high-fidelity mRNA amplification, called TALPAT (T7 RNA
polymerase promoter-attached, adaptor ligation-mediated, and
PCR amplification followed by in vitro T7-transcription) (Aoyagi
et al, 2003; Kobayashi et al, 2004; Nakamura et al, 2006).
As described in our previous report (Fukaya et al, 2006), semi-
quantitative reverse transcription (RT)–PCR and quantitative
real-time PCR were carried out using primer sets (Supplementary
Table 1). For semi-quantitative RT–PCR, we showed data within
linear range by performing 25–35 cycles of PCR. For quantitative
real-time PCR, the expression level of each mRNA was normalised
with that of GAPDH mRNA.
Immunohistochemistry
Specimens fixed in formalin and embedded in paraffin were cut
into 4mm sections, subsequently dewaxed, and dehydrated.
Endogenous peroxidase activity was blocked with 3% H2O2 in
methanol for 30min and endogenous biotin with a blocking kit
(Vector Laboratories, Burlingame, CA, USA). Antigen retrieval was
performed by autoclave for 10min at 1211Ci n1 0m M citrate buffer,
pH 6.0. Sections were blocked for DAKO protein block (DAKO,
Carpinteria, CA, USA), and incubated overnight at 41C with
diluted rabbit polyclonal antibody directed against human GLI1
(sc-20687, 1:100; Santa Cruz Biochemistry, Santa Cruz, CA, USA),
GLI2 (ab7181, 1:200; Abcam Ltd, Cambridge, MA, USA), PDGFRB
(sc-339, 1:200; Santa Cruz Biochemistry), EDNRA (E3651, 1:100;
SIGMA, St Louis, MO, USA), and mouse monoclonal antibody
directed against SMTN (MAB3242, 1:200; Chemicon International,
Tamecula, CA, USA). The next day, after washing the sections with
PBS containing 0.1% Tween-20, biotinylated secondary antibodies
were added for 30min at room temperature. Detection was carried
out with the Vectastain ABC Elite Kit (Vector Laboratories). After
extensive rinsing and incubation with an avidin-biotin immuno-
peroxidase complex, staining was visualised with the DAB system
(Nichirei, Tokyo, Japan), and the sections were counter-stained
with Mayer’s hematoxylin.
Cell lines and siRNA transfection
Seven diffuse-type GC-derived cell lines, HSC39, HSC43, HSC44,
HSC58, HSC59, HSC60, and KATOIII, and four intestinal-type
GC-derived cell lines, MKN7, MKN28, MKN74, and HSC57 were
maintained in RPMI1640 or Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum, 0.15% sodium bicarbo-
nate, 2mML -glutamine, and penicillin-streptomycin. An Hh-
pathway-specific antagonist cyclopamine or tomatidine, an in-
active but structurally related compound (Toronto Research
Chemicals, North York, Ontario, Canada) dissolved in 100%
ethanol was added to HSC60 at 30mM. After 6, 12, and 24h, cells
were collected and total RNA was isolated, respectively. Five
siRNA fragments were designed for suppressing GLI1, GLI2, SIP1,
ELK1, and MSX2 expression respectively, and the most effective
one was selected by quantitative real-time RT–PCR analysis. The
five siRNAs were GLI1 siRNA (SI00074802, QIAGEN, Valencia,
CA, USA), GLI2 siRNA (SI02634842, QIAGEN), SIP1 siRNA
(108633, Ambion, Austin, TX, USA), ELK1 siRNA (SI00300146,
QIAGEN), and MSX2 siRNA (SI00038031, QIAGEN). These siRNAs
were introduced to HSC60 using Dharma FECT1
t (Dharmacon, La
Fayette, CO, USA), following the procedure recommended by the
manufacturer. The RT–PCR analysis was carried out at 24h after
siRNA transfection.
Primary culture of mouse gastric epithelial cells
On postnatal day 4, the stomach of 57BL/6J mice was minced, then
suspended and sterilised with 10% antibiotic–antimycotic drugs
(Invitrogen, Carlsbad, CA, USA), and digested by incubation for
12min at 371C in 0.05%. collagenase 1 (Nitta Gelatine, Osaka,
Japan), and then manually dissociated with scissors, and incubated
for 5min at 371C with a 1:1 ratio of 0.5% Trypsin-EDTA
(Invitrogen) and Dispase 10000PU (Godo Shusei, Tokyo, Japan)
in PBS ( ). After being filtered with a 100mm cell strainer (Falcon,
Franklin Lakes, NJ, USA), the digested tissue fragments were
centrifuged for 5min at 1200r.p.m., resuspended in Defined
Keratinocyte-SFM (Invitrogen) with 1ml of supplement and
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culture dishes (IWAKI, Tokyo, Japan) and incubated at 371C
in a humidified atmosphere flushed with 5% CO2 in the air.
Twenty-four hours after plating, non-adhesive cells were
discarded. At 1 day after culture, 10mM of cyclopamine or
tomatidine was added.
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Figure 1 Semi-quantitative RT–PCR analyses of Hh signalling molecules, EMT regulators, and mesenchymal-related genes in three regions (pit, isthmus/
neck, and gland) of normal gastric mucosa, intestinal metaplasias (IMs), and two types of gastric cancers. Hh signalling molecules are expressed preferentially
in diffuse-type gastric cancers compared with IMs and intestinal-type gastric cancers, as reported previously (Fukaya et al, 2006). Three EMT regulators (SIP1,
SNAI2, and TWIST2) and 10 mesenchymal-related genes (FN1, SMTN, LMOD, MEF2C, PDGFRB, EDNRA, SLIT2, ROBO1, WNT5A, and ROR2) are preferentially
expressed in the pit region. These EMT regulators and mesenchymal-related genes are expressed highly and preferentially in diffuse-type gastric cancers
compared with the IMs and intestinal-type gastric cancers. EMTr, EMT regulator; M-1, three typical mesenchymal genes; M-2, three muscle-related
mesenchymal genes, and M-3, six other mesenchymal-related genes. GC, gastric cancer.
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Invasion of the GC HSC60 cells in vitro was measured by BD
BioCoat
t Matrigel
t Invasion Chamber (6-well) (Becton Dickinson
Biosciences, Bedford, MA, USA), according to the manufacturer’s
protocol. After SIP1 siRNA transfection, the cells were trypsinised
and 2ml of cell suspension (2 10
5 cellsml
 1) was added in
triplicate wells. For a cell growth assay, we counted the number of
cells at 24h after SIP1 siRNA transfection. For an invasion assay,
the cells that passed through the filter into the lower wells were
fixed and stained with 100% methanol and 1% Toluidine blue,
respectively. The number of invading cells was counted through a
microscope at 24h after SIP1 siRNA transfection.
RESULTS
Genome-wide mRNA expression profiling of primary
intestinal-type and diffuse-type GCs
To identify the specific genes for each type of GC, we selected 18
intestinal-type GCs and 12 diffuse-type GCs showing typical
characteristics on the form of cell growth (clustered or scattered)
and the degree of differentiation (well/moderate or poor), and
performed microarray analysis for obtaining genome-wide mRNA
expression profiles. First, we conducted unsupervised clustering
analyses using some gene sets, which were differentially expressed
depending samples. Most of the 12 diffuse-type GCs were able to
separate from the 18 intestinal-type GCs (data not shown),
suggesting the presence of a distinct difference on expression
profiles between the two types. Next, to compile a gene list for
identifying diffuse-type GC-specific signal pathways, we selected
genes by comparing the expression levels of the two types. A gene
was selected by Wilcoxon U-test (Po0.05) from genes with more
than a two-fold change on average. By this procedure, a total of 892
genes (704 genes specific to diffuse-type and 188 genes specific to
intestinal-type) were identified. The result of a two-dimensional
hierarchical clustering analysis of the 892 selected genes is shown
in Supplementary Figure 1. In the 188 intestinal-type-specific
genes, CCNDE, ERBB2, and GRB7, which have been reported to be
amplified and overexpressed in intestinal-type GC (Yasui et al,
2001), were included. In the 704 diffuse-type-specific genes, three
GLI1-target genes FOXM1, ISL1, and FOXF2 were included in
accordance with our previous report (Fukaya et al, 2006). More
interestingly, CDH1 encoding an epithelial cell marker E-cadherin,
which has been reported to be downregulated by an EMT
regulator, TWIST, in breast cancer (Yang et al, 2004), was found
only in intestinal-type GC, suggesting that diffuse-type GC may
show EMT. In accordance with this suggestion, nine other
mesenchymal-related genes (three muscle-related genes, SMTN,
LMOD, and MEF2C; one blood-related gene, PDGFRB; one
neuronal endocrine-related gene, EDNRA; two endothelium-
related genes, SLIT2 and ROBO1; a target gene of an EMT
regulator SIP1, WNT5A and its receptor, ROR2), were also found in
the diffuse-type-specific gene list, although expression of EMT
regulator genes (TWIST1, TWIST2, and SNAI2) other than SIP1
was never detected in the microarray platform used.
Normal gastric pit cells and diffuse-type GCs possess
mesenchymal-like gene expression
In the gastric corpus, the epithelium consists of three tubular units
from surface to base: a pit region containing mucus-secreting pit
cells, an isthmus/neck region containing stem cells, and a gland
region containing chief and parietal cells (Karam and Leblond,
1995). Intestinal-type GC is thought to develop from IM by
transdifferentiation, whereas diffuse-type GC is derived from stem
cell or the pit cell precursor (Ming, 1998; Yuasa, 2003). Therefore,
genes specifically expressed in the diffuse-type may be expressed
preferentially in the pit region among the three regions of the
gastric mucosa. Accordingly, we prepared RNA from each region
by LMD for RT–PCR as described in Materials and Methods. We
conducted semi-quantitative RT–PCR analysis of Hh signalling-
and EMT-related molecules in the three regions of the gastric
mucosa, IM, and two types of GC tissues. For semi-quantitative
RT–PCR, we performed 25–35 cycles of PCR, and showed data
within linear range.
Shown in Figure 1 are the results of semi-quantitative RT–PCR
on eight Hh signalling genes (SHH, IHH, DHH, BOC, PTCH, SMO,
GLI1, and GLI2), four GLI1 targets (ISL1, BMP4, FOXM1, and
FOXA2), four EMT regulator genes (S I P 1 ,S N A I 2 ,T W I S T 1 ,and
TWIST2), an epithelial cell marker (CDH1), three mesenchymal
markers (CDH2, VIM, and FN1, M-1 in Figure 1), and nine other
mesenchymal-related genes (SMTN, LMOD, MEF2C, PDGFRB,
EDNRA, SLIT2, ROBO1, WNT5A,a n dROR2, M-2 and M-3 in
Figure 1), in the RNA samples from the three regions of
gastric mucosa, four IMs, eight intestinal-type GCs and 10
diffuse-type GCs.
In our previous report (Fukaya et al, 2006), preferential
expression of most of the Hh signalling molecules (SHH, IHH,
DHH, PTCH, SMO, GLI1, GLI2, ISL1, BMP4, FOXM1, and FOXA2)
in diffuse-type GCs compared with IMs and intestinal-type GCs is
confirmed by quantitative real-time RT–PCR in the same sample
sets used in this paper. A new positive mediator of Hh signalling
EDNRA
PDGFRB
SMTN
EDNRA PDGFRB SMTN
Intestinal-type GC Diffuse-type GC
GLI2 GLI1
×200
×200 ×200
×200 ×200
×200 ×200
×200 ×200
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×200 ×400 ×200 ×400
A
B
Figure 2 Immunohistochemistry of Hh downstream targets (GLI1 and
GLI2) and mesenchymal-related genes (SMTN, PDGFRB, and EDNRA) in
normal gastric mucosas and in gastric cancer tissues. (A) Both GLI1 and
GLI2 are localised in the nuclei of the pit cells, and SMTN, PDGFRB, and
EDNRA are stained preferentially in the cytoplasm or cell membrane of the
pit cells. (B) SMTN, PDGFRB, and EDNRA are stained strongly in diffuse-
type gastric cancer cells compared with intestinal-type gastric cancer cells.
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mediator CDO expressed ubiquitously in the three regions of the
gastric mucosa, IM, and two types of GC tissues (data not shown).
The epithelial cell marker CDH1 was downregulated in the diffuse-
type compared with the intestinal-type.
In normal tissue, among the four EMT regulators, SIP1,
SNAI2, and TWIST2 were preferentially expressed in the pit
region, whereas TWIST1 was expressed only in the gland region.
In correspondence with SIP1, SNAI2, and TWIST2 expressions in
the pit region, FN1, SMTN, LMOD, MEF2C, PDGFRB, EDNRA,
SLIT2, ROBO1, WNT5A, and ROR2, preferentially expressed in the
pit region, whereas CDH2 expressed in the gland region
concordant with TWIST1 expression. In abnormal and malignant
tissue, EMT regulators and mesenchymal-related genes
were downregulated frequently in both the IMs and intestinal-
type GCs, while those expressions were maintained in the
diffuse-type GCs.
The results of RT–PCR analysis were confirmed by immuno-
histochemical analyses with GLI1, GLI2, SMTN, PDGFRB, and
EDNRA antibodies. Both GLI1 and GLI2 were localised in the
nuclei of the pit cells, and SMTN, PDGFRB, and EDNRA were
stained preferentially in the cytoplasm or membranes of the pit
cells (Figure 2A). These three genes were detected clearly in
diffuse-type GC cells, but scarcely detected in intestinal-type GC
cells (Figure 2B). These results suggest that, despite a differentiated
epithelial cell, the gastric pit cell exhibits the mesenchymal
phenotype, and that diffuse-type GC also maintains it. This
suggests the presence of cross talk between the Hh and EMT signal
pathways in both the pit cell and diffuse-type GC.
Cross talk between Hh and EMT pathways in gastric pit
cells and in diffuse-type GCs
As shown in Figure 1, in GC tissues, expression patterns of Hh-
and EMT-related genes including a Hh-primary transcriptional
target GLI1 and an EMT regulator SIP1 (indicated by a box)
were most likely to be similar among the samples examined (only
the no. 10 case in 10 diffuse-type GCs shows weak expression of
these genes, whereas nos. 1, 2, 3, 5, and 6 cases in eight intestinal-
type GCs showed weak). This observation suggested the presence
of cross talk between Hh and EMT pathways.
To examine whether the EMT regulator gene is a downstream
target of GLIs in Hh signalling, we first selected the GC cell line,
which most-closely mimics the normal pit cell and diffuse-type GC
phenotype in mRNA expression of Hh- and EMT-related genes
among 11 GC-derived cell lines. As shown in Figure 3A, the
diffuse-type GC cell lines except a HSC60 cell line (HSC39, HSC 43,
HSC44, HSC58, HSC59, and KATOIII) appeared to have down-
regulated expression of a number of the Hh- and EMT-related
genes. A tumour tissue provides various microenvironments (low
nutrition, hypoxia, and so on) for tumour cell growth. In a tumour
tissue, diffuse-type GC cells show scattered type growth by
interaction with myofibroblasts. In a cell culture, three cell lines
(HSC39, HSC58, and KATOIII) grow as spheroids. However, this
characteristic could not explain the downregulation in the cell
lines. Accordingly, the microenvironment and/or the interaction
may be required for the activation of the Hh and EMT pathways.
As shown in Supplementary Figure 2, both GLI1 and SIP1 were
never upregulated in a culture with a low serum level. Recently,
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Figure 3 Effect of treatment of Hh-signal-specific inhibitor, cyclopamine on gastric cancer cells. (A) RT–PCR analyses of Hh- and EMT-related genes in 11
gastric cancer cell lines. Only HSC60 cells most express Hh signalling, EMT regulator, and mesenchymal genes. (B) Cyclopamine treatment reduces mRNA
of not only six Hh-downstream genes (GLI1, GLI2, ISL1, BMP4, FOXM1, and FOXA2) but also three pit cell-expressing EMT regulators (SIP1, SNAI2, and
TWIST2) and eight mesenchymal-related genes (CDH2, PDGFRB, EDNRA, ROBO1, WNT5A, ROR2, MEF2C, and SMTN). (C) Quantitative real-time RT–PCR
analyses of Hh-downstream genes (GLI1 and GLI2) and EMT regulators (SIP1, SNAI2 and TWIST2) show the same results of the above semi-quantitative RT–
PCR. Results were calculated as meanþs.d. values from triplicate measurements of three separate experiments.
Extensive hedgehog signalling in the stomach
H Ohta et al
393
British Journal of Cancer (2009) 100(2), 389–398 & 2009 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
shypoxia-inducing factor-1 (HIF-1) has been reported to activate or
stabilise EMT regulators including TWIST and SNAIL (Gort et al,
2008; Sahlgren et al, 2008; Yang et al, 2008), but no report for such
activation in GLIs has been found. Therefore, to date, the
difference of EMT-related gene expression between cultured cells
and primary tumours can be postulated partly by hypoxia.
Although it was still unknown why the HSC60 cell line maintains
the predisposition of both the pit cell and diffuse-type GC in
expression of Hh signal- and EMT-related genes (Figure 3A), to
verify the above-mentioned hypothesis, we examined the effects of
treatment of an Hh signal pathway-specific inhibitor, cyclopamine
(Cooper et al, 1998; Chen et al, 2002) in this cell line. The mRNA
level of not only six Hh-downstream genes (GLI1, GLI2, ISL1,
BMP4, FOXM1, and FOXA2) but also three pit cell-expressing EMT
regulators (SIP1, SNAI2, and TWIST2) and their candidate
downstream genes (CDH2, PDGFRB, EDNRA, ROBO1, WNT5A,
ROR2, MEF2C, and SMTN) significantly decreased at 24h after
cyclopamine treatment compared with tomatidine, an inactive but
structurally related compound (Figure 3B). The results of semi-
quantitative RT–PCR of five key transcription factors (GLI1, GLI2,
SIP1, SNAI2, and TWIST2) were confirmed by performing
quantitative real-time PCR (Figure 3C).
Consecutively, GLI1 and GLI2 siRNA transfection were
performed to investigate whether SIP1 is a downstream target of
GLI. GLI1 siRNA transfection reduced the mRNA level of SIP1,
whereas GLI2 siRNA transfection never affected it (Figure 4A).
These results suggest that SIP1 is a downstream gene of GLI1 but
not of GLI2, although a decrease of SIP1 protein could not be
confirmed due to the low amount of SIP1 in HSC60 and the low
specificity of anti-SIP1antibodies obtained commercially and by
immunisation of our prepared-peptide sequences (data not
shown). Next, we conducted SIP1 siRNA transfection to examine
the downstream pathway of SIP1 (Figure 4B). SIP1 siRNA
treatment reduced mRNAs of SIP1, two other EMT regulators
(SNAI2, and TWIST2) and seven other genes (CDH2, PDGFRB,
EDNRA, ROBO1, WNT5A, ROR2, and MEF2C). Although an
epithelial cell marker CDH1 was never affected by SIP1 siRNA
treatment, WNT4, which has been reported to be involved in
epithelial transition (Stark et al, 1994), was clearly upregulated by
the treatment (Figure 4B, left panel).
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Figure 4 The EMT regulator gene SIP1 is a mediator for mesenchymal-like gene expression through Hh signalling in diffuse-type gastric cancer cells. (A)
Quantitative real-time RT–PCR analyses of SIP1 mRNA in GLI1 or GLI2 siRNA-treated HSC60 cells. GLI1 siRNA reduces SIP1 mRNA, whereas GLI2 siRNA
does not reduce SIP1 mRNA. Results were calculated as meanþs.d. values from triplicate measurements of three separate experiments. (B) Conventional
and quantitative real-time RT–PCR analyses of EMT regulators, Hh target genes, and mesenchymal-related genes in SIP1 siRNA-transfected HSC60 cells. In
accordance with a decrease of SIP1 mRNA, other EMT regulators (SNAI2 and TWIST2), and various mesenchymal-related genes (CDH2, PDGFRB, EDNRA,
ROBO1, WNT5A, ROR2, and MEF2C) are downregulated. On the other hand, mRNA levels of Hh target genes (ISL1, BMP4, FOXM1, and FOXA2) and CDH1,
an epithelial cell marker, are never affected, and WNT4, which is the other epithelial cell marker and involved in mesenchymal–epithelial transition (MET)
(Stark et al, 1994), is clearly upregulated by SIP1 siRNA treatment. Results of quantitative real-time RT–PCR were calculated as meanþs.d. values from
triplicate measurements of three separate experiments.
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FOXA2) were never affected by SIP1 siRNA treatment (Figure 4B,
left panel). The results of conventional RT–PCR in SIP1, SNAI2,
and TWIST2 were verified by quantitative real-time PCR
(Figure 4B, right panel). Those results of cyclopamine- (Figures
3B and 3C), GLI1 siRNA- (Figure 4A), and SIP1 siRNA (Figure 4B)-
treatment suggested that some mesenchymal phenotypes in
diffuse-type GC was exhibited by an EMT regulator SIP1 through
Hh signalling.
The expression pattern of three ligands, Ihh (pit), Shh (gland),
and Dhh (gland) in mouse gastric mucosa is similar to that in
human beings, and Hh signal activation is found in both pit cells
and parietal cells in murine glandular stomach (Van den Brink
et al, 2001; Fukaya et al, 2006). To this end, to investigate the
function of the Hh signal pathway in normal gastric mucosa, we
examined the effects of cyclopamine treatment in mouse primary
culture of gastric epithelial cells. Cyclopamine treatment reduced
mRNAs of not only pit cell expressing-Hh signalling molecules
(Gli1 and Gli2) but also EMT regulators (Sip1, Snai2, and Twist2)
(Figure 5A). Quantitative real-time PCR analyses showed the same
results (Figure 5B). Furthermore, mesenchymal-related genes
(Cdh2, Pdgfrb, Ednra, Robo1, Wnt5a, Ror2, Mef2c, and Smtn)
were also downregulated by cyclopamine treatment (Figure 5C).
These data suggest that mesenchymal-like gene expression of the
pit cell in both mice and humans is induced by Hh signal
activation.
Identification of cancer-specific Hh-downstream target
genes
An Hh-signal-specific inhibitor, cyclopamine, induces growth
inhibition in Hh-activating GC cells; meanwhile in normal gastric
epithelium, cyclopamine causes a block of pit cell differentiation
followed by epithelial hyperplasia (Fukaya et al, 2006). For
minimising the side effects in Hh-signal targeted cancer therapy,
identification of cancer-specific Hh-downstream genes such as
oncogenes is needed. Recently, evidence showing oncogene
activation by cancer-linked DNA hypomethylation has accumu-
lated (Feinberg et al, 2006). We previously reported 159 genes,
including oncogenes, which could be activated by GC-linked DNA
hypomethylation (Nishigaki et al, 2005). Among the gene list,
RT–PCR of four oncogenes (RHO6, RHOB, ELK1, and MSX2)i n
surgical specimens was performed. All four genes were suppressed
in normal gastric epithelium. Two genes, ELK1 and MSX2, of the
four genes were found to express preferentially in diffuse-type GC
(Figure 6A). Immunohistochemical analyses confirmed preferen-
tial expression of ELK1 and MSX2 proteins in diffuse-type GC cells
compared with intestinal-type GC cells. Representative results are
shown in Supplementary Figure 3. As shown in Figure 6B,
cyclopamine treatment reduced mRNA of ELK1 and MSX2,
suggesting both of the genes are regulated by Hh signalling.
GLI1 siRNA treatment reduced mRNA of ELK1 and MSX2
(Figure 6B). These results suggest that ELK1 and MSX2 may be
demethylated in diffuse-type GCs and then activated by GLI1.
Next, we investigated whether knockdown of ELK1 and MSX2
using siRNA affects cell growth. Treatment of each siRNA of ELK1
and MSX2 induced growth inhibition (53 and 41%, respectively) of
HSC60 at 4 days after transfection (Figure 6C). Double transfection
of these two siRNAs strongly inhibited cell growth (Supplementary
Figure 4). These data suggest that blocking of both the ELK1 and
MSX2 function could be an effective Hh-targeted cancer therapy.
SIP1 is involved in GC cell invasion
Finally, to investigate the biological implications of the Hh–EMT
pathway in diffuse-type GC, Matrigel invasion assays were
performed. Although no cell growth inhibition was observed at
24h after SIP1 siRNA transfection, the number of invaded HSC60
cells was significantly decreased after SIP1 siRNA transfection
compared with a control siRNA (Figure 7), suggesting that SIP1
was able to regulate genes critical to the invasion of diffuse-type
GC cells.
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Figure 5 Cyclopamine treatment in mouse primary culture of the gastric
epithelial cells. (A) In mice as well as in humans, not only Hh-downstream
targets (Gli1 and Gli2) but also EMT regulators (Sip1, Snai2, and Twist2) are
downregulated by cyclopamine treatment. (B) Quantitative real-time RT–
PCR analyses show the same results of the above conventional RT–PCR.
Results were calculated as meanþs.d. values from triplicate measurements
of three separate experiments. (C) Other mesenchymal-related genes
(Cdh2, Pdgfrb, Ednra, Robo1, Wnt5a, Ror2, Mef2c, and Smtn) are also
downregulated by cyclopamine treatment. As a control, Actb is shown in
Figure 5A.
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Our present results suggest the presence of cross talk between Hh and
EMT in gastric pit cells and in diffuse-type GC (Figure 8). The reason
why gastric pit cells exhibit the mesenchymal phenotype, despite
differentiating or differentiated epithelial cells, is unknown. Recently,
we reported that GSDM/GSDMA was a target of RUNX3 and LMO1 in
transforming growth factor-beta (TGF-b) signalling for apoptosis of
gastric pit cells (Saeki et al, 2007). Transforming growth factor-beta is
well known for inducing EMT as well as apoptosis of epithelial cells
(Zavadil and Bo ¨ttinger, 2005). Therefore, EMT may have a role in
migration of the differentiating pit cells toward the gastric lumen.
To address the molecular mechanism of the cross talk
between Hh and EMT, chromatin immunoprecipitation (ChIP)-
on-chip analysis is a hopeful tool for showing an in vivo direct
interaction of the SIP promoter with GLI1, or of SIP1-downstream
genes with SIP1. Although a GLI1 binding consensus sequence can
be found about 1kb upstream on the SIP1 promoter, there is no
report showing a GLI1 antibody suitable for ChIP. As shown in
Figure 6B, mRNAs of two GC-linked DNA hypomethylated
oncogene candidates, ELK1 and MSX2, were clearly reduced by
cyclopamine treatment and by GLI1 siRNA transfection. These
results suggest that GLI1 or other GLI1-target transcriptional
factors, including ISL1, FOXM1, FOXA2, and SIP1, may regulate
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Figure 6 Identification of cancer-specific Hh-target genes. (A) RT–PCR analyses of gastric cancer-linked DNA hypomethylated candidate genes (RHO6,
RHOB, ELK1, and MSX2) in normal gastric mucosa and cancer tissues. All four genes are suppressed in normal epithelium, and two genes ELK1 and MSX2 of
the four genes expressed preferentially in diffuse-type gastric cancer. (B) Cyclopamine (left panel) and GLI1 siRNA (right panel) treatment reduces ELK1 and
MSX2 mRNAs at 24h after treatment. Results of real-time RT–PCR were calculated as meanþs.d. values from triplicate measurements of three separate
experiments. As a control, Actb is shown in Figure 3B. (C) Treatment of ELK1 siRNA and MSX2 siRNA induces growth inhibition of HSC60 cells (lower
panel) in accordance with a decrease of ELK1 and MSX2 mRNAs (upper panel). Results of cell growth inhibition assays were calculated as meanþs.d. values
from triplicate measurements of three separate experiments. GC, gastric cancer.
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studies.
More than 70% of advanced GC patients show poor prognosis
(Wohrer et al, 2004; Lordick and Siewert, 2005). Therefore, a
new strategy or drug development is eagerly awaited. Advanced
diffuse-type GC is known to frequently show peritoneal metastasis
within 3 years. Our previous study (Fukaya et al, 2006) and this
study show that the Hh signal is activated in most diffuse-type
GCs, and that the Hh signal-specific inhibitor, cyclopamine,
effectively suppressed invasion as well as growth of Hh signal-
activated GC cells (Figure 7 and Fukaya et al, 2006). Therefore,
diffuse-type GC could be a therapeutic target of Hh-pathway-
specific inhibitors, especially for the protection of peritoneal
recurrence. Our proposed extensive Hh signal pathway containing
an EMT pathway could contribute to new drug development. As
shown in Figure 8, two transcription factors, GLI1 and SIP1, seem
to be the key molecules for the Hh–EMT pathway in diffuse-type
GC, because GLI1 regulates cell growth-related genes, such as
ELK1, MSX2, and FOXM1 (Kim et al, 2006; Yoshida et al, 2007),
and because SIP1 regulates cell invasion-related genes such as
EMT regulators (TWIST2 and SNAI2) (Taki et al, 2003; Yang et al,
2004), PDGFRB (Singh et al, 2007), and WNT5A (Kurayoshi et al,
2006). An increasing number of genes including oncogenes are
found to be normally methylated at promoters but hypomethylated
and activated in the corresponding tumours (Feinberg et al, 2006).
These include R-RAS and MASP in GC (Akiyama et al, 2003;
Nishigaki et al, 2005), MAGE1 in melanoma (De Smet et al, 1996),
S100A4 in colon cancer (Nakamura and Takenaga, 1998), PAX2 in
endometrial cancer (Wu et al, 2005), DNMT3A in testicular germ
cell tumours (Ishii et al, 2007), and various genes in pancreatic
cancer (Sato et al, 2003). ELK1 and MSX2, encoding transcription
factors, may belong to this class of oncogene. Double transfection
of ELK1 and MSX2 siRNAs to diffuse-type GC cells showed strong
cell growth inhibition compared with a single transfection (Figure
6C and D, and Supplementary Figure 4), suggesting that ELK1 and
MSX2 act independently on GC cell growth. Therefore, a genome-
wide search of the transcriptional downstream target gene of ELK1
and MSX2 in addition to GLI1 and SIP1 is thought to be important
for future identification of molecular targets of diffuse-type GC.
In summary, our study showed that genome-wide mRNA
expression profiling provides some hints for identifying specific
signal pathways, their cross talk, and some molecules aberrantly
expressed in the pathways in a certain type of cancer. However, the
sensitivity varies among microarray platforms, and most or all
major platforms have an insufficient sensitivity to detect a key
molecule, such as a growth factor or transcription factor, which
acts with a small expression. Improvement of the sensitivity is
needed for future cancer transcriptome.
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